The current fundraising campaign is intended, on the one hand, to industrialize the dopamine manufacturing process under anaerobic conditions and, on the other hand, to conduct the Phase III program designed to support the approval of the drug candidate in Europe and the United States as a priority.
Amount sought: $35 to $40 million dilutive and $10 million non-dilutive
Current series: Series A
Startup contact: veronique.foutel@inbrainpharma.com
Theme: Biotechnology
Applications: Medical device-assisted therapy
Partnerships and awards: Awards: i-Lab 2018, Deeptech 2019,
Laboratory: UMR-S 1172, EA7365
Institutions: LILLE UNIVERSITY HOSPITAL / INSERM/ University of Lille
Intellectual property: 1 patent on the method, a second patent relating to the drug candidate currently under review
Technology
inBrain Pharma's therapeutic innovation consists of the continuous intracerebroventricular administration of dopamine under anaerobic conditions in patients with advanced refractory Parkinson's disease suffering from complications related to levodopa-based therapies.
Applications
Treatment of neurodegenerative diseases, particularly Parkinson's disease (PD)
Benefits
Anaerobic dopamine (A-dopamine) significantly reduces motor impairment in patients with advanced Parkinson's disease who have become resistant to levodopa-based therapies.
Maturity
Clinical phase I/IIb ending on June 30, 2024
For more information
Contact your dedicated advisor